enVVeno Medical (NASDAQ: NVNO), a late-clinical stage medical device company setting new standards of care for the treatment of venous diseases, recently announced the pricing of an underwritten public offering. Led by existing institutional investors, the offering involved the issuance and sale of 4,285,715 shares of the company’s common stock (or pre-funded warrants in lieu thereof) at a public offering price of $3.50 per unit. enVVeno expected to receive aggregate gross proceeds from the offering of about $15.0 million. The offering was anticipated to close on or about September 30, 2024, subject to customary closing conditions.
To view the full press release, visit https://ibn.fm/LdAMR
About enVVeno Medical Corporation
enVVeno Medical is an Irvine, California-based, late clinical-stage medical device company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company’s lead product, the VenoValve(R), is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (“CVI”). The company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe(R). CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve(R) and enVVe(R) are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve(R) is currently being evaluated in the SAVVE U.S. pivotal trial and the company is currently performing the final testing necessary to seek approval for the enVVe(R) pivotal trial.
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]
InvestorWire is powered by IBN